UK markets close in 4 hours 1 minute
  • FTSE 100

    7,769.00
    +7.89 (+0.10%)
     
  • FTSE 250

    19,913.23
    -2.28 (-0.01%)
     
  • AIM

    866.93
    +1.52 (+0.18%)
     
  • GBP/EUR

    1.1369
    -0.0020 (-0.18%)
     
  • GBP/USD

    1.2365
    -0.0042 (-0.34%)
     
  • BTC-GBP

    18,578.88
    -134.26 (-0.72%)
     
  • CMC Crypto 200

    520.46
    -6.72 (-1.28%)
     
  • S&P 500

    4,060.43
    +44.21 (+1.10%)
     
  • DOW

    33,949.41
    +205.57 (+0.61%)
     
  • CRUDE OIL

    82.25
    +1.24 (+1.53%)
     
  • GOLD FUTURES

    1,932.00
    +2.00 (+0.10%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     
  • HANG SENG

    22,688.90
    +122.12 (+0.54%)
     
  • DAX

    15,158.83
    +25.98 (+0.17%)
     
  • CAC 40

    7,096.60
    +0.61 (+0.01%)
     

154,112 Orion Corporation A shares converted into B shares

Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
25 JANUARY 2023 at 9.00 EET

154,112 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 154,112 A shares have been converted into 154,112 B shares. The conversion has been entered into the Trade Register on 25 January 2023.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,032,382 A shares and 107,101,896 B shares. The number of votes of the company's shares is after the conversion 787,749,536.

Orion Corporation

Jari Karlson

CFO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.